Argent Biopharma Limited Change of OTCQB Company Code

RNS Number : 6271P

Argent Biopharma Limited

23 May 2024

 

 

23 May 2024

 

Argent BioPharma Ltd.

 

Change of OTCQB Company Code

 

Argent BioPharma Ltd. (Argent BioPharma or the Company) advises that as of 20 May 2024, the Company's new trading code on the OTCQB changed to RGTLF.

 

This adjustment aligns with the Company's recent change in registered name with the Australian Securities and Investments Commission (ASIC) and trading code on the ASX and LSE.

 

 

-Ends-

 

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]	Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

 

 

 

About Argent BioPharma

 

Argent BioPharma purpose is to address unmet medical needs through the pioneering integration of Nanotechnology and Multidisciplinary research methods. Our approach heralds a transformative shift in healthcare, combining the power of multi-targeted drug therapies with precision nanoscale delivery to enhance treatment efficacy while reducing side effects. Central to our ethos is making these innovative treatments accessible, ensuring they reach those underserved by current medical solutions. As we endeavour to become globally recognized in the life science industry, we are committed to bridging healthcare gaps, redefining industry standards, and providing impactful solutions and hope to communities worldwide.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCPPUUWAUPCUQW